Every 8-K that Inspire Medical Systems, Inc. (INSP) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow INSP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INSP filings page.
Inspire Medical Systems reported Q2 2026 results with revenue of $200.6 million, down 7.6% from Q2 2025, mainly from U.S. coding and reimbursement pressures, partly offset by international growth. Gross margin improved to 85.5%, operating expenses fell 7.4% to $172.0 million, and net earnings were $0.3 million, or diluted EPS of $0.01; adjusted diluted EPS was $0.14.
Operating cash flow rose to $23.2 million from $2.7 million, and cash, cash equivalents, and investments increased to $415.2 million as of June 30, 2026. For 2026, the company now guides revenue to $835–$875 million, adjusted operating margin of 4–6%, and adjusted EPS of $1.05–$1.45. It also launched Project Horizon, a strategic growth plan expected to incur $20–$25 million of pre-tax restructuring charges and to create about $30 million of annualized investment capacity for revenue growth initiatives, with most actions targeted for completion by Q3 2026 and substantially complete by year-end.
Inspire Medical Systems, Inc. appointed Michael H. Carrel to its Board of Directors as a Class III director, effective July 20, 2026. His term runs until the company’s 2027 Annual Meeting of Stockholders, and he will also serve on the Organization and Compensation Committee and the Quality, Product Supply and Technology Committee.
Carrel is President, Chief Executive Officer and director of AtriCure, Inc. and has held multiple leadership roles at publicly traded healthcare and technology companies. Under the Non-Employee Director Compensation Policy, he will receive a $55,000 annual cash board retainer, $7,500 annually for each committee, a $300,000 initial restricted stock unit grant vesting over three years, and $200,000 in annual RSU awards following each annual meeting, plus standard director indemnification.
Inspire Medical Systems, Inc. reported that Board member Casey M. Tansey has decided to retire from its Board of Directors and the committees on which he serves, effective July 30, 2026, and will not stand for re-election at the 2027 Annual Meeting of Stockholders. The company states that his decision is not due to any disagreement regarding operations, policies, or practices.
Tansey has served on the Board for more than eighteen years, representing U.S. Venture Partners and leading Inspire’s Series A financing in November 2007. He has been involved through the company’s founding, initial public offering, and subsequent growth. Inspire expects to announce a new director to replace him in the near future.
Inspire Medical Systems, Inc. filed a Form 8-K to share that it will participate in meetings with investors and analysts in June 2026. The company is using a formal investor presentation for these meetings, which is provided as Exhibit 99.1 and posted on its investor relations website.
The presentation is furnished under Regulation FD, meaning it is for informational purposes and is not treated as filed financial statements or incorporated into other securities filings unless specifically referenced.
Inspire Medical Systems, Inc. reported results from its 2026 annual stockholder meeting and related governance and compensation changes. Stockholders approved an amended and restated 2018 Incentive Award Plan authorizing 9,903,857 common shares for awards, including 2,600,000 additional shares, and added one-year minimum vesting, tighter dividend rules on unvested awards, and extended the plan through March 6, 2036.
Investors also approved an amendment to the certificate of incorporation to phase out the classified board structure and move to annual director elections beginning with the 2029 annual meeting. All proposals on the ballot, including director elections, auditor ratification, executive pay on an advisory basis, and a potential adjournment authority, received sufficient support. Approximately 25,287,595 shares, about 88% of outstanding common stock, were represented at the meeting.
Inspire Medical Systems reported solid growth for 2025 while signaling a slower 2026 and governance changes. Revenue rose 14% to $911.9 million, with gross margin of 85.4% and net income of $145.4 million, or $4.89 per diluted share. Adjusted EBITDA reached $200.6 million and operating cash flow was $117.0 million, supporting $175 million of share repurchases in 2025.
Fourth quarter 2025 revenue grew 12% to $269.1 million, and net income was $136.1 million, or $4.66 per diluted share, helped by a large tax benefit from releasing a valuation allowance. For 2026, the company now guides revenue to $950 million–$1.0 billion, implying 4%–10% growth, with adjusted operating margin of 6%–8% and adjusted EPS of $1.85–$2.35, reflecting reimbursement and coding uncertainties for the Inspire V procedure.
The filing also outlines a proposal to declassify the board, moving to annual director elections after a phase-in, and bylaw amendments to remove the “for cause only” director removal provision, subject to shareholder approval at the 2026 annual meeting.
Inspire Medical Systems, Inc. reported that it has issued a press release with certain preliminary, unaudited financial results for the quarter and full year ended December 31, 2025, which are still subject to closing procedures and internal control review.
The company’s board appointed Matthew J. Osberg as Chief Financial Officer, to become effective the day after Inspire files its Annual Report on Form 10-K for 2025. He will also serve as principal financial officer and principal accounting officer. His employment agreement provides a $650,000 annual base salary, a target annual cash bonus equal to 70% of base salary, a $600,000 cash sign-on bonus, and long-term equity incentives in the form of performance stock units and restricted stock units valued at $1,500,000 each on the grant date.
As part of the planned finance leadership transition, Richard J. Buchholz has been appointed interim Chief Financial Officer and designated as interim principal financial officer and interim principal accounting officer through the filing of the 2025 Form 10-K. Inspire also plans investor and analyst meetings in January 2026, supported by an investor presentation made available on its website.
Inspire Medical Systems, Inc. expects to release a significant portion of the valuation allowance on its U.S. deferred tax assets in the fourth quarter of fiscal 2025. The company estimates this action will create an income tax benefit of $90 million to $100 million for the year. This tax benefit is expected to increase diluted earnings per share by approximately $3.00 to $3.30 for the same period. These figures are based on current assumptions and are described as forward-looking, with actual results potentially differing due to various risks and uncertainties discussed in the company’s other regulatory filings.
Inspire Medical Systems reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and furnished an investor presentation for upcoming meetings with investors and analysts.
The materials are provided as Exhibits 99.1 (press release) and 99.2 (presentation). The company noted these items are furnished, not filed, under the Exchange Act. The investor presentation is also available on the company’s Investor Relations website.
Inspire Medical Systems, Inc. filed a current report describing upcoming investor and analyst meetings in October 2025. The company is using a prepared slide presentation for these meetings, which is furnished as Exhibit 99.2 and made available on its investor relations website.
The filing also lists a related press release as Exhibit 99.1. The company clarifies that the presentation materials and related disclosure are furnished, not filed, so they are not subject to certain Exchange Act liability provisions or automatically incorporated into other securities law filings.
Inspire Medical Systems (INSP) announced that Chief Financial Officer Richard J. Buchholz has notified the company he will step down to pursue other professional opportunities. Mr. Buchholz and the company entered a Transition and Separation Agreement under which his resignation will be effective on the earlier of December 31, 2025 or the date a permanent successor CFO commences employment. He will remain principal financial and accounting officer through that date and then serve as a financial advisor through February 28, 2026 while receiving base salary and benefits.
The agreement provides for a cash payment equal to nine months of his 2025 annual base salary and up to nine months of COBRA coverage. The company has engaged a leading executive search firm to recruit a new CFO. The filing discloses customary confidentiality, non-disparagement and release provisions and incorporates the full separation agreement as Exhibit 10.1 and a press release as Exhibit 99.1.
Inspire Medical Systems disclosed that its Board has authorized the repurchase of up to $200.0 million of the company’s outstanding common stock. The filing indicates the board approved a buyback authorization but does not include details on timing, methods, or the pace of repurchases.
The filing also furnishes the company press release as Exhibit 99.1 and includes Inline XBRL cover page tags. No financial results, program specifics, or additional transaction terms are provided within this report.